SPOTIFY
1.2.2021 23:03:12 CET | Business Wire | Press release
Today Spotify (NYSE: SPOT) launches its service in South Korea, giving Korean listeners access to over 60 million tracks and over 4 billion playlists from around the world. As the world’s most popular audio streaming subscription service, Spotify offers an effortlessly simple interface, an innovative technology framework, everyday new music discovery and algorithmic recommendations personalized to each listener’s music taste. This launch brings Spotify’s total number of markets to 93.
As the sixth-largest music market in the world*, South Korea is a critical next step in Spotify’s global expansion journey. Not only is South Korea among the most digitally inclusive markets in the world, but it is also widely recognized as a cultural and music epicenter, in part due to the global phenomena K-Pop. Since Spotify debuted its first K-Pop playlist in 2014, the share of K-Pop listening on the platform has increased by more than 2,000%. With this launch, Spotify plans to accelerate the growth of Korea’s entire music streaming ecosystem, benefitting creators, labels, distributors and fans.
“We always want to be where the listeners and artists are, and Korea is rich in both,” said Alex Norström, Chief Freemium Business Officer of Spotify. “This launch presents a massive opportunity for us to not only further our mission of bringing new and quality content to more audiences, but also help local Korean artists tap into Spotify’s 320 million listeners worldwide. We hope to create more opportunities for Korean artists across all genres to be discovered by listeners around the world.”
Spotify has uniquely tailored the music experience for each market. As a part of today’s launch, Spotify is introducing a range of new playlists made exclusively for South Korea. These playlists offer curated and the latest music from our team of Korean music experts, across some of the most popular genres. These include:
- TOP Playlists: Korean Music Hot Now , FRESH! New Music Korea , Hot Hits Korea , Korean Music Rising , Today's Drama OST Hot Now , K-Pop Daebak and more
- Genre Playlists : TrenChill K-R&B , TrenChill K-Hip Hop , K-HIP-HOP +82 , K-Are & Be , In The K-Indie , Korean City Pop , K-Rock Spirit , Folk & Acoustic Hot Now , Orchestra Korean Ballad and more
- Thematic Playlists : You Did Well , The End of the Day , So Cool Driving , Brain Rest 432Hz , Lullaby zZZ , Transcendental Game Play , Running K-Pop , GAYO Instrumentals , Spring Music , Into the Rain , Next Page of the Break-up , Kitchen Melodies and more
- ‘Starring’ playlists : This Is BTS , This Is BLACKPINK , This Is Stray Kids , This Is NCT , This Is TWICE , This is Taeyeon , This Is JAY Park , This Is CHUNG HA , This Is Loco and more
These new playlists will join Spotify’s K-Pop genre hub that encompasses a wide range of Korean music, including K-pop, Hip Hop, Indie, OST, R&B and more, as well as ‘RADAR Korea’, a playlist uncovering fresh K-music finds and a part of Spotify’s global emerging artist program. The hub is localized in over 72 countries, including Russia, India, Brazil and the UAE.
In Korea, new listeners can try out Spotify Premium 7 days-free on their mobile phone with no credit card information and a total of 3 months-free with credit card information, if subscribed before the end of June 2021. Listeners can engage with Spotify across a wide range of devices and app integrations including Instagram, Facebook, Samsung mobile and TV, LG TV, Microsoft Xbox, Bose and more.
The Spotify app is available to download for both Premium Individual and Duo plans. To enjoy music the way you want it, download the Spotify app today via the Android or iOS app store or by heading to www.spotify.com/kr-ko/ .
Click here for further imagery.
* According to IFPI (https://www.ifpi.org/wp-content/uploads/2020/07/Global_Music_Report-the_Industry_in_2019-en.pdf )
About Spotify Technology S.A.
Spotify transformed music listening forever when we launched in 2008. Our mission is to unlock the potential of human creativity by giving a million creative artists the opportunity to live off their art and billions of fans the opportunity to enjoy and be inspired by these creators.
Today, with over 60 million tracks and over 4 billion playlists, we are the world’s most popular audio streaming subscription service with a community of more than 320 million listeners across 93 markets.
We use our Investors and For the Record websites as well as other social media listed in the “Resources – Social Media” tab of our Investors website to disclose material company information. For more information, images, or to contact the press team, head over to https://newsroom.spotify.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005846/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom